The U.S. Food and Drug Administration (FDA) is considering new and innovative diabetes drug from the laboratories of Novo Nordisk. Victoza, the new diabetes drug from the danish pharmaceutical giant, prevents heart attacks, strokes and cardiovascular deaths.
According to the opinion of scientists from the University of North Carolina, Chapel Hill, new diabetes drug Victoza is able to treat much better than its analogs do. Actually, Victoza is only the second diabetes drug ever that able to prevent heart attacks, strokes, and cardiovascular deaths. The first was Jardiance (Eli Lilly and Boehringer Ingelheim), which showed impressive results as well. But Victoza impressed much stronger, assures Dr John Buse, the University of North Carolina:
“There’s a building momentum that maybe we do need to rethink the way diabetes is cared for in America.”
But FDA intends to keep new drugs off the market, that’s its new strategy, which may hurt patients. An innovative drug from Novo Nordisk labs could save health and even lives, but not now. According to FDA, maybe, later–after the thorough consideration. Results of Victoza’s tests published in the New England Journal of Medicine.
In fact, the results shown to the doctors on June 14, too. At the annual meeting of the American Diabetes Association, doctors could see figures and statistics. In total, 9,340 patients were randomly assigned to receive either Victoza or placebo for a median of 3.8 years. For those on Victoza, 13% had a heart attack, stroke or death, compared to 14.9% on placebo, a 13% decrease in risk. The cardiovascular mortality level (22%) and death from any cause (15%) were also statistically significant.